Arcturus Therapeutics (ARCT) director awarded 15,000 stock options at $7.30

Rhea-AI Filing Summary

Arcturus Therapeutics Holdings Inc. director John Markels received a grant of stock options as part of his 2026 annual board compensation. The award covers options to buy 15,000 shares of common stock at an exercise price of $7.30 per share, expiring on June 5, 2036. These options vest monthly over one year from the grant date, and following this grant he holds stock options for 15,000 shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Markels John

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	15,000	$0.00	--

Holdings After Transaction: Stock option (right to buy) — 15,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 15,000 options Exercise price: $7.30 per share Expiration date: June 5, 2036 +2 more

5 metrics

Option grant size 15,000 options Stock option (right to buy) granted to director

Exercise price $7.30 per share Conversion or exercise price of options

Expiration date June 5, 2036 Option expiration for 15,000-share grant

Underlying shares 15,000 shares Common stock underlying the option grant

Total options after grant 15,000 options Total derivative holdings following transaction

Key Terms

Stock option (right to buy), Grant, award, or other acquisition, vest monthly over a one year period, Board of Directors

4 terms

Stock option (right to buy) financial

"security_title: "Stock option (right to buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

vest monthly over a one year period financial

"Shares underlying the option vest monthly over a one year period"

Board of Directors financial

"as a member of the Board of Directors of the Issuer"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/15/2026 - 05:01 PM Accepted by SEC EDGAR 06/15/2026 - 05:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Markels John

(Last) (First) (Middle)

C/O ARCTURUS THERAPEUTICS HOLDINGS INC.

10285 SCIENCE CENTER DRIVE

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arcturus Therapeutics Holdings Inc. [ ARCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)(1)	$7.3	06/05/2026		A		15,000		(1)	06/05/2036	Common Stock	15,000	$0.00	15,000	D

Explanation of Responses:

1. Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

	/s/ Ilan Katz, attorney-in-fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Arcturus Therapeutics (ARCT) director John Markels report on this Form 4?

John Markels reported receiving a stock option grant for 15,000 shares of Arcturus Therapeutics common stock. The options are part of his 2026 annual board compensation and give him the right to buy shares at a fixed exercise price.

How many Arcturus Therapeutics (ARCT) shares are covered by the new option grant?

The option grant covers 15,000 underlying shares of Arcturus Therapeutics common stock. This entire amount was acquired in a single award and represents his total option holdings reported following the transaction on the Form 4.

What is the exercise price and expiration date of John Markels’ Arcturus (ARCT) options?

The options have an exercise price of $7.30 per share and expire on June 5, 2036. This means he can choose to buy shares at $7.30 any time before the expiration date, once the options are vested.

How do the new Arcturus Therapeutics (ARCT) options vest for director John Markels?

The 15,000-share option grant vests in monthly installments over a one-year period from the grant date. This gradual vesting schedule is typical for director compensation and requires continued board service to receive the full award.

Is this Arcturus Therapeutics (ARCT) Form 4 an open-market purchase or a compensation grant?

This Form 4 reports a compensation-related grant, not an open-market stock purchase. The transaction code is “A” for a grant or award, and the footnote explains it is the 2026 annual grant for Markels as a member of the Board of Directors.